Introduction
The translocation that gives rise to the Ph (Philadelphia chromosome), encoding the tyrosine kinase fusion protein, BCR-ABL, is found in 95% of patients with chronic myeloid leukemia (CML). 1 Unregulated constitutive BCR-ABL activity contributes to malignant transformation by increasing proliferation and decreasing apoptosis of CML cells, by reducing their sensitivity to regulation by bone-marrow stromal cells, 2, 3 and perhaps by reducing genetic instability. 4 Elucidation of this mechanism has spurred the development of rationally designed drugs that target BCR-ABL tyrosine kinase activity. The first of these to be developed was imatinib, a 2-phenylaminopyrimidine that inhibits the activity of BCR-ABL and, to varying degrees, several other tyrosine kinases. [5] [6] [7] [8] Imatinib induces durable responses, prolongs event-free and progression-free survival in patients with CML, and is the current standard of care for this disease. 9, 10 Imatinib has activity in all phases of CML, but the most extensive and durable responses are seen in chronic-phase patients, particularly those newly diagnosed with the disease. In the IRIS study, at 72 months, survival free from transformation in patients given imatinib as initial therapy was estimated at 93%, and overall survival at 88%. 11 Despite the impressive efficacy of imatinib, suboptimal response and even treatment failure are sometimes seen. A number of factors may underlie this (Figure 1) , including: (i) biological factors, such as the baseline presence or later emergence of BCR-ABL mutations 12 and other genetic variations; 13 (ii) clinical features, such as the disease status of the patient, or the Sokal risk score at baseline 14, 15 and (iii) pharmacokinetic (PK)-related factors affecting exposure to imatinib, which have recently been associated with clinical response. 15, 16 In this article, we review the factors that affect PK plasma exposure, the plasma PK-response correlation, and the use of imatinib blood-level testing in various patient groups. The relationship between plasma and intracellular imatinib levels is also briefly considered.
Factors affecting imatinib plasma PK exposure
Imatinib has favorable PK characteristics, including rapid absorption and essentially complete bioavailability, a proportionate dose-response relationship, and a half-life of B18 h that permits once-daily dosing. 17, 18 This results in steady-state plasma concentrations being achieved after 5-7 days of therapy. 17 However, although intrapatient variability in imatinib trough blood concentrations is small (Mahon et al., J Clin Oncol 2008; 26: abstract 7087), the interpatient variability in exposure to imatinib that results from a given dosing regimen can be substantial. [15] [16] [17] Peng et al. 17 investigated the PK and PD (pharmacodynamics) of imatinib in a phase I study involving 64 adult patients with Ph þ CML. The study reported considerable variability in drug exposure among patients, with a coefficient of variation of 40-60%. A French study, reported by Picard et al. 16 assessed trough plasma imatinib concentrations (C min ) in 68 patients with CML who had been receiving imatinib therapy at 400 or 600 mg/day for at least 12 months. Imatinib plasma trough concentrations ranged from 181 to 2947 ng/ml, with a mean ( ± s.d.) of 1058±557 ng/ml for the 400 mg/day dose, and 1444±710 ng/ ml for the 600 mg/day dose. Data from the phase III IRIS study reported by Larson et al. 15 also showed high interpatient variability in plasma imatinib concentrations. Trough plasma imatinib was measured at steady state before morning dosing on day 29 in 351 patients receiving 400 mg/day. The overall mean C min was 979 ± 530 ng/ml, with a coefficient of variation of 54.1%. CGP74588, the active N-desmethyl metabolite of imatinib, had a similar coefficient of variation for trough concentrations (43.6%). 15 The reasons for these variations in imatinib plasma concentrations are not fully defined, but may include: (i) incomplete adherence with the therapeutic regimen; (ii) patient demographic factors such as sex, age, body weight and body surface area (BSA); (iii) differential absorption from the gastrointestinal tract; (iv) intrinsic variability in metabolizing enzyme activity (CYP3A4) and enzymatic drug-drug interactions and (v) differential binding of imatinib by a 1 -acid glycoprotein in the plasma.
18-23
Incomplete adherence with the therapeutic regimen With the advent of targeted, oral anticancer agents prescribed as chronic therapy, adherence is becoming a major concern. 24 For patients with life-threatening diseases, X95% adherence is generally considered the goal. 25 However, patients may overestimate their adherence to oral cancer therapies by a factor of two in discussions with their physicians. 26 A recent study showed that adherence to imatinib therapy among some patients with Ph þ CML is less than ideal (Tsang et al., J Clin Oncol 2006; 24: 330s. abstract 6119). In an analysis of pharmacy records for 4043 patients prescribed imatinib, only 41% of patients were 490% compliant with the drug over 14 months of treatment. Adherence to therapy seemed to decline after B4 months of treatment; this would have affected imatinib plasma exposure, and probably clinical response too.
Patient demographic factors
A variety of patient demographic factors, including sex, age, body weight and BSA, have been examined for their impact on imatinib exposure. A study of 64 adult patients given imatinib found no significant correlation between body weight or BSA and imatinib exposure. 17 A subanalysis of data from 351 patients in the IRIS trial identified a weak correlation between trough plasma concentrations of imatinib and both body weight and BSA. 15 Plasma imatinib concentrations were also slightly higher in females than in males, although this may have been because of differences in body weight. The same analysis also showed a weak correlation between plasma imatinib concentration and patient age.
As interpatient variability in trough concentrations of imatinib is substantial even among patients with similar demographic traits, the effects of body weight, BSA, sex and age on imatinib exposure are unlikely to be clinically significant in the vast majority of patients. However, if a patient's body weight is unusually low or high (o50 or 4120 kg), it may be useful to assess imatinib exposure by monitoring drug concentrations.
Differential absorption from the gastrointestinal tract
Imatinib is freely soluble in water and, after oral administration, is well absorbed from the gastrointestinal tract with a time to peak drug concentration of 2-4 h. 17 It is 98% bioavailable, and absorption is not significantly affected by food (Reckmann et al., Proc Am Soc Clin Oncol 2001; 20: abstract 1223), however, the extent of absorption may be affected by gastrointestinal anatomic abnormalities or disease states, 23 and these should therefore be considered when imatinib is dosed.
Variability in CYP enzyme activity and enzymatic drugdrug interactions
Imatinib is metabolized by the cytochrome P450 system, mainly through the CYP3A4 isoform, with minor contributions from CYP1A2, CYP2D6, CYP2C9 and CYP2C19. 27 The main metabolite of imatinib is CGP74588, an N-desmethylated piperazine derivative that has biological activity similar to that of the parent drug, and an area under the curve for plasma concentration against time that is B16% of the area under the curve for imatinib. 28 Variability in CYP3A4 activity among individuals is substantial, 29 and may contribute to some of the variation in imatinib exposure among patients. In addition, CYP3A4 activity can be altered by other drugs that patients may be taking in addition to imatinib: drugs that inhibit CYP3A4 increase imatinib plasma exposure, whereas drugs that induce CYP3A4 may decrease plasma exposure. 18 Some herbal medicines (for example, St John's wort) and consumer products (for example, grapefruit juice) can also affect CYP3A4 activity and hence imatinib PK. 30, 31 Physicians should be aware of these possibilities when treating patients with imatinib. Studies investigating the significance of polymorphisms of cytochrome P450 enzymes in determining plasma concentrations and response to therapy are needed to understand the significance of these factors better.
Differential binding of imatinib by a 1 -acid glycoprotein
It has been suggested that a 1 -acid glycoprotein in the plasma may bind imatinib, thereby reducing the free concentration of the drug and blocking its ability to enter leukemic cells. 19, 32 Studies on imatinib plasma concentrations (including the Larson and Picard papers 15, 16 have tended to measure total imatinib rather than the unbound fraction. To date, the only method for measuring free imatinib is equilibrium dialysis, which takes a long time (minimum of 6 h dialysis before the imatinib assay can be performed).
A recent PK-PD analysis by Widmer et al., 33 using data from 58 patients, did not determine a straightforward correlation between free imatinib plasma exposure and clinical response, but further experiments may be warranted to clarify the role of variability in a 1 -acid glycoprotein activity on imatinib response.
Correlation of imatinib plasma PK with clinical outcomes

Treatment response
Two recent studies have shown a correlation between imatinib trough plasma concentration and clinical response. 15, 16 Picard et al. 16 examined the relationship between trough plasma imatinib concentration and cytogenetic and molecular responses in patients with CML. Mean trough plasma imatinib was significantly higher in patients with a complete cytogenetic response (CCR) at the time of assessment (1123 ± 617 ng/ml; n ¼ 56) than in those without (694±556 ng/ml; n ¼ 12) (P ¼ 0.03). Concentrations were also significantly higher in patients with a major molecular response (MMR) (1452 ± 649 ng/ml; n ¼ 34), defined as a reduction in transcript levels to p0.1% on the international scale, than in those without an MMR (869 ± 428 ng/ml; n ¼ 34) (Po0.0001). There was no difference in mean daily imatinib dose between the two groups.
Larson et al. 15 correlated mean trough plasma imatinib concentrations obtained for CML patients at day 29 of imatinib treatment with cytogenetic and molecular responses, event-free survival and adverse event rates over 5 years of treatment in the phase III IRIS study. Patients were divided into four quartiles according to their trough plasma imatinib concentration. Quartile 1 (Q1) contained patients with the lowest imatinib concentrations (o647 ng/ml), whereas quartile 4 (Q4) contained those with the highest (41170 ng/ml). The middle two quartiles (Q2 and Q3) (647-1170 ng/ml) were combined for subsequent analyses. Cumulative estimated rates of both CCR and MMR differed significantly among the three groups (Q1, Q2-3 and Q4) ( Table 1) . In both cases, the differences were mainly attributable to lower response rates in the lowest quartile (Q1 vs Q2-Q4: CCR, P ¼ 0.005; MMR, P ¼ 0.008). Imatinib trough plasma concentrations were also significantly higher in patients who achieved a CCR (n ¼ 297) than in those who did not (n ¼ 54): 1009±544 ng/ml vs 812±409 ng/ml, respectively (P ¼ 0.01, t-test; P ¼ 0.004, Wilcoxon test). On multivariate analysis, imatinib trough concentrations and Sokal risk score were both independent predictors of the likelihood of CCR. There was a trend towards better event-free survival at 5 years in the quartiles with higher trough imatinib concentrations (Q1 78%, Q2-Q3 83%, Q4 89%), but this did not reach statistical significance with the available follow-up data (P ¼ 0.16). The authors concluded that patients were more likely to achieve a satisfactory response to therapy if an adequate imatinib trough plasma concentration was achieved and maintained.
The therapeutic concentration window for imatinib has not been fully defined. Picard et al. 16 reported that plasma imatinib concentrations 41002 ng/ml were significantly associated with the presence of MMR, with a sensitivity of 77% and a specificity of 71%. Similarly, Larson et al. 15 reported that the mean C min in patients who achieved a CCR was 1009 ng/ml. On the basis of the available data, they suggested that maintaining plasma trough concentrations at or above the mean population concentration of B1000 ng/ml could be important for achieving improved rates of CCR and MMR. 16 If trough imatinib concentrations are to be maintained at or above 1000 ng/ml, some patients will achieve this goal at the standard imatinib dose of 400 mg/day, but others may require dose escalation to 600 or 800 mg/day.
However, it may ultimately be difficult to identify a definitive therapeutic concentration window, as some patients experience a good clinical response with imatinib blood concentrations below 1000 ng/ml, whereas others respond poorly despite concentrations above 1000 ng/ml. Furthermore, studies so far have examined plasma imatinib concentrations at a single time point; the clinical impact of maintaining imatinib concentrations over a sustained period remains unknown. Factors such as intrapatient variability over time, interactions with other medications and the effect of dose changes and treatment interruptions have not been fully explored.
The possibility of an imatinib therapeutic concentration window has also been suggested in other diseases, such as acute lymphoblastic leukemia, gastrointestinal stromal tumor and hypereosinophilic syndrome. 
Adverse events
In a PK-PD analysis by Widmer et al., 33 a statistically significant correlation was observed between free drug exposure and toxicity in CML. However, in the IRIS study, adverse event rates were similar among the quartiles of trough plasma imatinib concentrations. 15 Higher imatinib concentrations were associated with greater risk of fluid retention, rash, myalgia or anemia, but less risk of fatigue, abdominal pain, joint pain or neutropenia. The authors suggested that the risk of some adverse effects may be influenced by disease burden, or the speed of response to therapy. Discontinuations because of adverse events did not vary significantly among the quartiles. Thus, the role of imatinib plasma concentrations in predicting toxicity remains to be established. It has been suggested that plasma concentrations can be used to guide dose adjustments when patients experience adverse events, 34 but clinical judgment remains paramount in these decisions. The specific role of plasma concentrations in guiding treatment decisions is being investigated in prospective studies.
Monitoring imatinib concentrations
Trough plasma concentrations
The traditional method of estimating PK exposure is to measure the area under the curve of plasma concentration vs time. Alternatives include peak concentrations (typically achieved 1-2 h after imatinib dosing) and trough concentrations. For clinical monitoring purposes, trough plasma concentrations of imatinib have been most widely adopted, as they are easiest to obtain. The studies reported by Picard et al. and Larson et al. 15, 16 took the trough concentration measurement approach, with trough blood samples collected before morning dosing at steady state. Plasma concentrations of imatinib were then determined using a sensitive and specific LC-MS/MS method (HPLC coupled with tandem mass spectrometry) suitable for routine drug concentration monitoring. The assays were based on rapid, simple and sensitive protocols that had been validated earlier. 35, 36 There are other methods, such as HPLC coupled with UVdiode array detection, which can be used to quantify imatinib. However, these alternative assays must be validated to current guidelines stipulated by the FDA or another regulatory body, and ideally also cross validated against the already validated LC-MS/MS reference method.
In addition to these imatinib quantification methods, procedures are also in development for measuring concentrations of the second-generation tyrosine kinase inhibitors, nilotinib 37 and dasatinib. However, there are currently no published data on the correlation between plasma concentrations of these drugs and response or associated adverse events. Other variables may also make correlations of plasma levels of second-generation tyrosine kinase inhibitors with response to therapy more complex. For example, the short half-life of dasatinib (o5 h) and the use of twice-daily dosing regimens may make trough plasma levels less relevant. Studies of the clinical significance of plasma levels of these agents are required to further determine their value.
Intracellular imatinib concentrations
Strategies based on the measurement of intracellular imatinib concentrations are also under investigation. As kinase inhibition is the key determinant of imatinib efficacy, intracellular concentrations might be expected to be more clinically relevant than trough plasma concentrations. However, the practical difficulties associated with measuring intracellular imatinib concentrations mean that such tests cannot be used in routine clinical practice.
The activity of cellular uptake/efflux transporters may affect intracellular imatinib concentrations independently of plasma concentrations. Several studies have confirmed that imatinib interacts with the multidrug transporter proteins, MDR1 (multidrug resistance protein 1, also known as P-glycoprotein) [38] [39] [40] and MXR (multixenobiotic resistance protein, also known as breast-cancer resistance protein). [41] [42] [43] Increased expression of these two efflux proteins reduces intracellular concentrations of imatinib and decreases the antiproliferative effects of the drug. 40, 41, [44] [45] [46] Furthermore, in a recent study of 90 imatinibtreated CML patients, single nucleotide polymorphisms in the gene encoding MDR1 seemed to affect both plasma concentrations of imatinib and clinical response to the drug. 47 Further studies are warranted to examine the potential role of these single nucleotide polymorphisms in the early identification of individuals with CML who may not respond optimally to standard imatinib therapy.
Active transport processes also mediate the influx of imatinib. 46 In the leukemic cell line CCRF-CEM and its drugresistant subline VBL100, the uptake of imatinib was temperature dependent, indicative of an active uptake process. Imatinib uptake was also significantly decreased by incubation with inhibitors of the human organic cation transporter 1 (hOCT1), and thus may be hOCT1-mediated. 48 The level of hOCT1 mRNA is significantly lower in cytogenetic non-responders, 49, 50 and differential hOCT1 function is a significant determinant of molecular response in imatinib-treated patients. 51 However, the activity of these transporters is still measured primarily for research purposes, and the tests are not widely available.
Clinical rationale for blood-level testing
Pharmacokinetics monitoring is widely used in many other branches of medicine, such as neurology, cardiology and psychiatry, but has not yet been widely applied in clinical oncology practice. Although the supporting data are currently limited, particularly with respect to prospective studies, there are reasonable grounds to consider blood-level testing as an aid to clinical decision making. There are several scenarios in which it could be of value: for example, when patients have a suboptimal response or treatment failure, when adverse reactions are unusually severe, or when the clinician suspects either a drug-drug interaction or that the patient is not adhering to the treatment regimen. If low concentrations are found, it is important to ascertain the underlying cause (for example, poor adherence or drug-drug interactions).
Suboptimal response or treatment failure
In cases of suboptimal response or treatment failure, measurement of trough plasma imatinib concentration could potentially assist the clinician in deciding whether to escalate the dose. For example, if the imatinib plasma concentration is low, dose escalation could be considered. However, in the absence of prospective trial data clarifying the role of blood-level testing in these patients, dose escalation may still be advisable even when the plasma concentration is not low, if the patient has a suboptimal response and minimal toxicity. High-dose imatinib (800 mg as 400 mg twice daily) has been reported to produce earlier and more molecular and cytogenetic responses than the standard dose of 400 mg daily. 52 There are also several reports of dose escalation being successfully used to overcome resistance to standard-dose therapy in some patients. [53] [54] [55] Plasma concentrations of imatinib should be considered as one of several elements that influence decision making, and results should always be interpreted in the clinical context. Plasma imatinib concentrations in the range associated with a lower probability of response should not by themselves be considered an indication to increase the dose, if a patient is currently responding well to treatment.
Unusually severe adverse reactions
Measurement of imatinib plasma concentrations could aid clinical decision making in patients suffering from severe adverse effects, as these may sometimes be associated with high imatinib plasma concentrations. Blasdel et al.
34 measured plasma imatinib in three patients receiving imatinib 300 mg twice daily, with unusually severe toxicity: grade 3 myalgia, transfusion-dependent erythropoietin-refractory anemia associated with bone-marrow hypoplasia and diffuse pulmonary infiltrates. They found imatinib concentrations that were considerably higher than expected. In two of the three patients, dose reduction resolved the most troublesome adverse effects, with repeat blood-level testing showing that concentrations were still within the proposed therapeutic range. In the third patient, imatinib was permanently discontinued. However, as this was a very small group of patients, no firm conclusions can be drawn about either the importance of blood-level testing, or the most appropriate treatment decision in patients with severe adverse effects who have elevated plasma imatinib concentrations.
Although there is evidence of a link between imatinib exposure and toxicity in CML, 33 the correlation between plasma imatinib concentrations and adverse events may not be linear. In the IRIS trial, some adverse events were seen more frequently in patients with intermediate or lower plasma concentrations. 15 Decisions regarding the need for treatment interruption, dose reduction, or change of therapy should thus be based on the overall clinical situation. However, measurement of plasma concentrations may assist in some difficult cases. Additional studies are ongoing, and will help to define the role of plasma imatinib measurement more clearly.
Suspected drug-drug interaction
As imatinib is metabolized by the cytochrome P450 system, mainly through the CYP3A4 isoform, polymorphisms in CYP3A4 can affect its functionality, and potentially, its metabolism. Drugs that inhibit or induce CYP3A4 can also alter imatinib PKs. Inhibitors of CYP3A4, such as ketaconazole 22 may increase imatinib concentrations; conversely, inducers of CYP3A4, such as rifampicin, 21 some antiepileptic drugs 56 and the herbal remedy St John's wort, 30, 31 may decrease imatinib concentrations. Patients should thus be asked about their use of over-thecounter as well as prescription medications.
A drug-drug interaction may be suspected in patients who are taking other medications and do not have the expected response to imatinib. If measurement shows an imatinib concentration that is lower than expected, and the patient is thought to be adhering to their therapy regimen, it may be appropriate to consider changing the medication suspected to be interacting with imatinib, or raising the imatinib dose. Whichever treatment decision is made, further monitoring is needed to ascertain whether a 'therapeutic' concentration of imatinib is achieved.
When a patient is started on a new medication that has potential for interactions with imatinib, blood-level testing may help in assessing any effect on imatinib plasma concentrations that could lead to decreased efficacy or increased toxicity.
Suspected non-adherence
Non-adherence to imatinib treatment is a potential cause of treatment failure or suboptimal response. The half-life of imatinib is B18 h; 17 a drug holiday of just 1 week would thus completely eliminate the drug from the plasma, and shorter drug holidays could significantly affect the plasma concentrations achieved. The significance of intermittent vs sustained declines in plasma levels has not been determined. Hence, a plasma imatinib measurement that is lower than expected may provide an opportunity for detailed discussion of adherence with the patient. For example, Mahon et al. 57 report a patient who was initially classified as failing imatinib treatment. After careful questioning about her very-low plasma imatinib concentration, she eventually admitted that she regularly induced vomiting after taking her medication.
Monitoring for adherence may require an unannounced measurement of plasma concentration. This could therefore measure non-trough levels of imatinib, which would be less predictive for response and toxicity. However, for patients with a suspected adherence problem, blood-level testing can still be an important tool in assisting in the management of the patient.
Special circumstances
There are other circumstances in which measuring imatinib plasma concentration may be of clinical value. For example, in patients undergoing surgical procedures that could impair the absorption of imatinib, blood-level testing before and after surgery might help to determine the effect of the procedure on imatinib absorption. Similarly, patients with other medical conditions that may affect the absorption of imatinib could be monitored carefully with assessment of plasma imatinib concentrations.
Clinical use of imatinib plasma concentrations
Measuring trough plasma concentrations provides an additional tool for the management of patients taking imatinib, although the results should always be interpreted in the context of the clinical evidence for the specific patient. The main objective of therapy in CML is to achieve and maintain cytogenetic and molecular response, and this usually guides therapeutic decisions. Assessment of the response to therapy should be the first step in evaluating the need for a change in therapy, whether by increasing the dose of imatinib or by switching to another tyrosine kinase inhibitor. The European LeukemiaNet and the National Comprehensive Cancer Network have each provided recommendations on treatment decision making based on cytogenetic and molecular response data. 9, 10 Imatinib bloodlevel testing may be considered whenever a patient fails to achieve a satisfactory response in accordance with these recommendations. The presence of toxicity can also usually be assessed clinically, and this can guide decision making on whether treatment interruptions and/or dose reductions are required.
On the basis of the results of the study by Larson et al., 15 it seems appropriate to measure trough plasma imatinib concentrations on day 29 from the start of therapy. However, no study has yet addressed the impact of changes in therapeutic strategy based on trough plasma concentrations. Such studies should be conducted, but until these data are available, information on trough plasma concentration should be valued as a prognostic indicator rather than a therapeutic tool. In scenarios such as those discussed above, measuring imatinib plasma concentrations may be of assistance in managing the patient. However, in the absence of prospective data supporting the maintenance of imatinib trough plasma concentrations at or above a particular threshold (for example, 1000 ng/ml), the temptation to manage patients to a certain plasma level should be avoided. The 1000 ng/ml threshold discussed by Larson et al. and Picard et al. 15, 16 should be considered as a population mean value associated with clinical response, and not the target concentration for a specific patient, as there are various factors in addition to plasma exposure that affect response. Thus, whenever measured, plasma concentrations should be interpretedFand decisions madeFin the context of all the clinical information available.
In addition, there are still gaps in the understanding of sequential measures of trough plasma concentrations, the concentrations attained in patients receiving different doses and schedules (for example, twice daily), and the changes in plasma concentrations after alterations in dose. These would be important studies to help understand further the value of measuring imatinib plasma concentrations. A study examining the measurement of imatinib plasma concentrations over a sustained period of time is also warranted, as no published work to date has examined the clinical impact of plasma imatinib concentrations measured at more than one time point. Such work would be valuable in assessing the impact of dose adjustments and treatment interruptions, as well as in understanding the effect of maintaining plasma imatinib concentrations at or above certain thresholds (for example, 1000 ng/ml). Continuous monitoring could also improve patient adherence to therapy. However, even based on a single plasma imatinib measurement, physicians should investigate the underlying cause of a high-or low-imatinib concentration if the clinical response or side-effect profile is questionable. Imatinib bloodlevel testing may offer a positive way to initiate an evidencebased discussion of adherence, drug-drug interactions, unusual adverse reactions or poor response to treatment.
Conclusions and future prospects
Although imatinib is easy to administer and has generally favorable PK characteristics, the plasma exposure to imatinib that results from a given dosing regimen varies significantly among patients. Several factors may underlie this, including adherence to therapy, variability in the metabolism of imatinib by the CYP enzyme system and drug-drug interactions. 18, [19] [20] [21] [22] [23] Although a plasma trough imatinib concentration of 1000 ng/ ml or above has been associated with achievement of cytogenetic and molecular responses in CML, 15, 16 there is variability in the test, and clinical parameters can guide medical management of most patients. Measurement of plasma levels may be useful in some specific scenarios, such as where poor compliance is suspected. However, in these instances a random plasma level would be most appropriate.
Further studies are warranted to define more clearly the minimal trough imatinib concentrations that are effective in different patient populations, particularly with respect to different Sokal risk scores, hOCT1 transporter activities and BCR-ABL mutations. Additional studies are required to examine whether imatinib plasma concentrations vary in patients with extreme body weights; if so, these patients may require different doses to achieve the same drug concentration, and thereby increase the likelihood of a favorable outcome.
Monitoring imatinib blood concentrations has the potential to aid in the management of some patients with CML, but considerable work is still required to evaluate the variability of the test, the variations with dose changes, and biological and clinical outcomes. If these benefits can be realized, bloodlevel testing may well become an important tool in the management of CML. Until then, it should be considered an investigational tool.
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